We'll call our meeting to order.
We want to thank our witnesses for coming. It's good to have you with us, for sure.
We have Sally Brown, Joyce Reynolds, and Paul Hetherington. We know all of you. We've seen your faces many times and we welcome you back.
I see Anne Ferguson is here, as well as Dr. Marangoni.
Thank you very much for being here. We're looking forward to this panel on trans fats. It's a very important subject not only in Canada but around the world, and we want to inform the committee as much as we possibly can.
Speaking to the committee, first of all, I want to thank Madame Gagnon for assisting by chairing the last meeting. Thank you very much. I understood you did such a good job my job is in jeopardy here on the committee—I've heard that from my colleagues already—but thank you very much.
And congratulations to Mrs. Kadis on being elected vice-chair.
We have a new member—well, actually new or old: Madame Beaumier was with us a number of years ago. I welcome you back to the committee. It's good to have you here.
To inform the committee, we were to have witnesses from Dow AgroSciences Canada Inc. who could not make the flight out of Calgary today, so they will not be with us. We have a briefing, which you have in your text.
We want to start with our witnesses and will open the floor, first of all, to Sally Brown, chief executive officer of Heart and Stroke Foundation of Canada and the co-chair of the task force.
The floor is yours, and we'll proceed.